First Time Loading...

Mereo Biopharma Group PLC
NASDAQ:MREO

Watchlist Manager
Mereo Biopharma Group PLC Logo
Mereo Biopharma Group PLC
NASDAQ:MREO
Watchlist
Price: 3 USD 1.69% Market Closed
Updated: Mar 28, 2024

Intrinsic Value

MREO latest financial reports are more than 2 years old.
MREO's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. [ Read More ]

The intrinsic value of one MREO stock under the Base Case scenario is 0.67 USD. Compared to the current market price of 3 USD, Mereo Biopharma Group PLC is Overvalued by 78%.

Key Points:
MREO Intrinsic Value
Base Case
0.67 USD
Overvaluation 78%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Mereo Biopharma Group PLC

Backtest MREO Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling MREO stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

How can I assist you today?

Provide an overview
of Mereo Biopharma Group PLC's business.

What risks and challenges
does Mereo Biopharma Group PLC face in the near future?

Summarize the latest earnings report
of Mereo Biopharma Group PLC.

Provide P/E
for Mereo Biopharma Group PLC and its competitors.

Financials

Balance Sheet Decomposition
Mereo Biopharma Group PLC

Current Assets 54.2m
Cash & Short-Term Investments 42.1m
Receivables 10.7m
Other Current Assets 1.4m
Non-Current Assets 26.4m
PP&E 1.6m
Intangibles 24.8m
Current Liabilities 17.5m
Accounts Payable 1.9m
Accrued Liabilities 4.8m
Other Current Liabilities 10.8m
Non-Current Liabilities 5.4m
Long-Term Debt 4.6m
Other Non-Current Liabilities 797k
Efficiency

Earnings Waterfall
Mereo Biopharma Group PLC

Revenue
7.1m GBP
Cost of Revenue
-1.9m GBP
Gross Profit
5.3m GBP
Operating Expenses
-36.9m GBP
Operating Income
-31.7m GBP
Other Expenses
5.6m GBP
Net Income
-26.1m GBP

Free Cash Flow Analysis
Mereo Biopharma Group PLC

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

MREO Profitability Score
Profitability Due Diligence

Mereo Biopharma Group PLC's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

21/100
Profitability
Score

Mereo Biopharma Group PLC's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

MREO Solvency Score
Solvency Due Diligence

Mereo Biopharma Group PLC's solvency score is 52/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Low D/E
Long-Term Solvency
Short-Term Solvency
52/100
Solvency
Score

Mereo Biopharma Group PLC's solvency score is 52/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

MREO Price Targets Summary
Mereo Biopharma Group PLC

Wall Street analysts forecast MREO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MREO is 5.1 USD with a low forecast of 4.04 USD and a high forecast of 7.35 USD.

Lowest
Price Target
4.04 USD
35% Upside
Average
Price Target
5.1 USD
70% Upside
Highest
Price Target
7.35 USD
145% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

MREO Price
Mereo Biopharma Group PLC

1M 1M
-20%
6M 6M
+129%
1Y 1Y
+295%
3Y 3Y
-9%
5Y 5Y
-54%
10Y 10Y
-54%
Annual Price Range
3
52w Low
0.71
52w High
4.05
Price Metrics
Average Annual Return -37.2%
Standard Deviation of Annual Returns 31.75%
Max Drawdown -95%
Shares Statistics
Market Capitalization 420.7m USD
Shares Outstanding 140 243 400
Percentage of Shares Shorted 2.21%

MREO Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Mereo Biopharma Group PLC Logo
Mereo Biopharma Group PLC

Country

United Kingdom

Industry

Biotechnology

Market Cap

420.7m USD

Dividend Yield

0%

Description

Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. The firm is focused on oncology and rare diseases. The firm is focused on development and commercialization of therapeutic pharmaceutical products. Its pipeline consists of a diversified portfolio of clinical-stage product candidates, Etigilimab (MPH-313) for patients with advanced or metastatic solid tumors; Alvelestat (MPH-966) for the treatment of severe Alpha-1 Antitrypsin Deficiency (AATD) and coronavirus disease; Setrusumab (BPS-804) for the treatment of Osteogenesis Imperfecta (OI); Navicixizumab (OMP-305B83) for the treatment of platinum-resistant ovarian cancer; Acumapimod (BCT-197) for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD) and Leflutrozole (BGS-649) for the treatment of male infertility associated with hypogonadotropic hypogonadism (HH).

Contact

London
Fourth Fl, 1 Cavendish Place
+443330237300.0
http://www.mereobiopharma.com/

IPO

2016-06-09

Employees

49

Officers

Co-Founder, CEO & Executive Director
Dr. Denise Scots-Knight Ph.D.
Co-Founder, General Counsel & Company Secretary
Mr. Charles Sermon
Co-Founder & Chief Business Officer
Dr. John P. Richard M.B.A.
Chief Financial Officer
Ms. Christine Fox CPA
Chief Scientific Officer
Dr. John A. Lewicki Ph.D.
Senior VP & Therapeutic Head
Dr. Jackie Parkin
Show More
Chief of Patient Access & Commercial Planning
Ms. Alexandra Hughes-Wilson
Senior Vice President of Clinical Development
Dr. Suba Krishnan
Senior VP and Head of Pharmaceutical Development & CMC
Mr. Bo Kara
Show Less

See Also

Discover More
What is the Intrinsic Value of one MREO stock?

The intrinsic value of one MREO stock under the Base Case scenario is 0.67 USD.

Is MREO stock undervalued or overvalued?

Compared to the current market price of 3 USD, Mereo Biopharma Group PLC is Overvalued by 78%.